Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent
- 13 October 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 49 (10) , 1264-1275
Abstract
Historically, locally advanced pancreatic adenocarcinoma (LAPDAC) was considered a palliative condition. Advances in treatment have resulted in studies reporting survival after neoadjuvant treatment and surgery similar to earlier disease stages. However, there is no consensus on optimal LAPDAC management. Our aim was a systematic review of published evidence on LAPDAC treatment strategies with curative intent. Twenty-eight studies defining LAPDAC as per established criteria and reporting outcomes after neoadjuvant treatment with a view to resection were included. Primary outcomes were resection rate and proportion of curative resections. Secondary outcomes were postoperative mortality, progression-free survival, and overall survival. Neoadjuvant treatment varied significantly, most common being the combination of folinic acid, fluorouracil, irontecan, and oxaliplatin. Median percentage of patients proceeding to surgery after completion of neoadjuvant pathway was 33.5%. Median resection rate was 25%. Median R0 resection was 80% of resected patients. These outcomes ranged 0% to 100% across studies. Ninety-day postoperative mortality ranged from 0% to 5%. Median progression-free and overall survival for resected patients were 12.9 and 30 months, respectively, versus 13.2 months overall survival for unresected patients. In conclusion, although there is wide variability in reported LAPDAC resection rates post–neoadjuvant chemotherapy, retrospective data suggest that neoadjuvant treatment followed by surgery results in improved survival.Keywords
This publication has 46 references indexed in Scilit:
- FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center ExperienceThe Oncologist, 2013
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinomaBMC Cancer, 2012
- Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancerRadiation Oncology, 2012
- Arterial Resection During Pancreatectomy for Pancreatic CancerAnnals of Surgery, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Advanced pancreatic carcinoma: current treatment and future challengesNature Reviews Clinical Oncology, 2010
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Most Pancreatic Cancer Resections are R1 ResectionsAnnals of Surgical Oncology, 2008
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 2006